Introduction to TGFBR1, A Potential Drug Target (G7046)

Target Name: TGFBR1

NCBI ID: G7046

TGFBR1

Introduction to TGFBR1, A Potential Drug Target

Targeted therapies have revolutionized cancer treatment by focusing on specific molecules that drive tumor growth and progression. One such molecule is the transforming growth factor beta receptor 1 (TGFBR1), which has emerged as a promising drug target and biomarker for various malignancies. In this article, we will delve into the significance of TGFBR1 and explore its potential in cancer management.

TGFBR1: An Overview

TGFBR1 is a transmembrane serine/threonine kinase receptor that belongs to the transforming growth factor-beta (TGF-β) superfamily. It plays a critical role in mediating TGF-β signaling, a pathway involved in cell growth, differentiation, and immune response. TGFBR1 acts as a gatekeeper, ensuring the appropriate activation of downstream signaling cascades.

TGFBR1 in Normal Cellular Processes

In normal physiological conditions, TGF-β ligands bind to TGFBR1, leading to downstream signaling events that regulate cell proliferation, apoptosis, and extracellular matrix production. TGFBR1 acts as a tumor suppressor in early stages of cancer, inhibiting uncontrolled cell division and promoting cell cycle arrest. Additionally, it participates in tissue repair mechanisms, immune tolerance, and embryogenesis.

TGFBR1 Dysregulation in Cancer

Alterations in TGFBR1 expression, mutations, or aberrant signaling can have detrimental effects on cellular homeostasis and contribute to carcinogenesis. TGFBR1 can switch its role from a tumor suppressor to a promoter during cancer progression, triggering epithelial-mesenchymal transition (EMT), which promotes the invasion, migration, and metastasis of tumor cells.

Furthermore, TGFBR1 dysregulation can render cancer cells resistant to conventional therapies, facilitating tumor survival and recurrence. Its overexpression has been reported in several cancers, including breast, lung, pancreatic, and colorectal, and is associated with poor prognosis, advanced disease stage, and reduced overall survival.

TGFBR1 as a Drug Target

The dysregulation and oncogenic properties of TGFBR1 make it an attractive target for drug development in cancer therapy. Inhibiting TGFBR1 can impede tumor growth, suppress EMT, and sensitize cancer cells to chemotherapy or radiotherapy.

Small molecules and monoclonal antibodies are among the potential therapeutic agents currently being investigated to target TGFBR1. These agents inhibit TGFBR1 signaling by blocking its kinase activity or interfering with ligand-receptor interaction. Initial preclinical studies have shown promising results in various cancer models.

TGFBR1 as a Biomarker

In addition to being a therapeutic target, TGFBR1 has emerged as a potential biomarker for cancer diagnosis, prognosis, and treatment response. The abnormal expression of TGFBR1 in cancer tissues and its correlation with clinical outcomes make it a valuable indicator in patient stratification and personalized medicine.

Researchers have identified TGFBR1 mutations, gene amplifications, and alterations in downstream signaling components as potential biomarkers for selecting patients who may benefit from targeted therapy against TGFBR1. Additionally, TGFBR1 expression levels in circulating tumor cells, circulating tumor DNA, or exosomes hold promise as non-invasive biomarkers for monitoring disease progression and treatment response.

Clinical Trials and Future Directions

Clinical trials targeting TGFBR1 are currently underway in a variety of cancer types, evaluating the safety and efficacy of TGFBR1 inhibitors both as monotherapy and in combination with other treatment modalities. These trials seek to validate TGFBR1's potential as a therapeutic target and biomarker and bring this new class of drugs closer to clinical practice.

Looking ahead, further research is necessary to elucidate the complex mechanisms underlying TGFBR1 dysregulation in cancer and identify optimal treatment strategies. Moreover, there is a need to develop reliable and standardized methods for detecting TGFBR1 alterations, considering their potential clinical impact.

Conclusion

TGFBR1 represents a promising drug target and biomarker in cancer management. Its crucial role in mediating TGF-β signaling and its dysregulation in various malignancies make it an attractive candidate for targeted therapies. By inhibiting TGFBR1, we can potentially suppress tumor growth, prevent metastasis, and sensitize cancer cells to conventional treatments. Furthermore, TGFBR1 has the potential to serve as a valuable biomarker for patient stratification, treatment response monitoring, and personalized medicine. Continued research and clinical trials will be instrumental in harnessing the full potential of TGFBR1 in improving cancer outcomes and paving the way for precision oncology.

Protein Name: Transforming Growth Factor Beta Receptor 1

Functions: Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation

The "TGFBR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TGFBR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets